CA-VERIMATRIX
1.9.2022 17:46:43 CEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it will highlight its powerful content protection, anti-piracy and enterprise cybersecurity technologies for streaming services providers, broadcasters, telcos and operators from September 9-12 during this year’s IBC conference at RAI Amsterdam.
The company’s IBC showcase follows a fast-growing number of technology partnerships that underscore the appeal of the cloud-based Verimatrix Streamkeeper solution that’s designed to enable battle-ready, yet streamlined and cost-effective protections for content delivered via nearly any platform type. The IBC conference serves as one of the media and entertainment industry’s most notable venues to feature Verimatrix’s unique zero-code telemetry approach that makes anti-piracy and cybersecurity not only simple and fast, but also cost-effective and designed to encourage integration with other related M&E providers.
IBC Show Highlights:
- Product demos - Verimatrix XTD (Extended Threat Defense), Verimatrix Streamkeeper, Verimatrix Secure Delivery Platform and Verimatrix VCAS (IPTV/DVB)
- 3D hologram – A holographic presentation of Verimatrix Counterspy, the company’s proprietary anti-piracy and app protection security agent that uses proprietary zero code technology
- Partner recognition – Technology partners are critical to Verimatrix’s success, and the company will feature key partners on its partner wall, during demos and in booth videos
The company is set to host two in-booth mixers at its IBC Booth 1.C23 on September 9 and 10 with TiVo, a leader in DVR and advanced television, as well as The Goose House, a popular esports community that Verimatrix sponsors. Verimatrix is also sponsoring a Media and Entertainment Services Alliance (MESA) networking event scheduled for 8-10 p.m. on September 9 at Café Black.
“Today’s countless ways of delivering and consuming entertainment require a modern approach to anti-piracy and cyberattack prevention, but they must be offered as business enablers and value providers versus costs centers. Verimatrix Streamkeeper and Verimatrix XTD are two new solutions engineered to do just that,” said Asaf Ashkenazi, CEO at Verimatrix. “Our theme for IBC 2022 is ‘STREAM ON! Game changing security for streaming & beyond’ and we are excited to showcase a stunning new booth design where we will showcase our latest products alongside our award-winning, legacy content security solutions.”
Verimatrix Streamkeeper stands as a cybersecurity and anti-piracy gamechanger. Its users can implement a comprehensive set of content protection and anti-piracy solutions such as Multi-DRM, Watermarking, App Shield and other countermeasures that allow users to hunt down and take out OTT pirates who often take advantage of premium content that’s left unprotected. Streamkeeper includes Verimatrix's Counterspy technology – the autonomous injection of an anti-piracy and app protection security agent that uses proprietary zero code technology that brings deep, defensive countermeasures as well as the monitoring of clients without the hassle of a huge integration effort.
Verimatrix XTD defends against endpoint attacks by monitoring apps, APIs and unmanaged devices; illuminating blind spots and preventing firewall intrusions -- threats that are not typically covered by existing cybersecurity solutions.
Verimatrix Streamkeeper info is available at www.verimatrix.com/products/streamkeeper.
Verimatrix XTD info is available at www.verimatrix.com/products/extended-threat-defense.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
